Trial Watch-Oncolytic viruses and cancer therapy

Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the develo...

Full description

Saved in:
Bibliographic Details
Published inOncoimmunology Vol. 5; no. 2; p. e1117740
Main Authors Pol, Jonathan, Buqué, Aitziber, Aranda, Fernando, Bloy, Norma, Cremer, Isabelle, Eggermont, Alexander, Erbs, Philippe, Fucikova, Jitka, Galon, Jérôme, Limacher, Jean-Marc, Preville, Xavier, Sautès-Fridman, Catherine, Spisek, Radek, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.02.2016
Subjects
Cavatak
GM-CSF
JX-594
ONCOS-102
Reolysin
Review
talimogene laherparepvec
Cavatak
JX-594
GM-CSF
Reolysin
talimogene laherparepvec
ONCOS-102
Online AccessGet full text

Cover

More Information
Summary:Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Equally contributed to this work.
Share senior co-authorship.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.1080/2162402X.2015.1117740